Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Nan Miles Xi, Yu-Yi Hsu, Qianyu Dang & Dalong Patrick Huang. (2022) Statistical learning in preclinical drug proarrhythmic assessment. Journal of Biopharmaceutical Statistics 32:3, pages 450-473.
Read now
Read now
Icilio Cavero & Henry Holzgrefe. (2014) Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative. Expert Opinion on Drug Safety 13:6, pages 745-758.
Read now
Read now
Icilio Cavero. (2012) 2011 Annual Meeting of the Safety Pharmacology Society: an overview. Expert Opinion on Drug Safety 11:2, pages 341-353.
Read now
Read now
Icilio Cavero. (2011) 10th annual meeting of the Safety Pharmacology Society: an overview. Expert Opinion on Drug Safety 10:2, pages 319-333.
Read now
Read now
Nenad Sarapa & Margaret R Britto. (2008) Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opinion on Drug Safety 7:3, pages 305-318.
Read now
Read now
Nenad Sarapa$suffix/text()$suffix/text(). (2007) Quality assessment of digital annotated ECG data from clinical trials by the FDA ECG warehouse. Expert Opinion on Drug Safety 6:5, pages 595-607.
Read now
Read now
Frédéric Bouder. (2007) A Case Study of Long QT Regulation: A Regulatory Tennis Game Across the Atlantic. Journal of Risk Research 10:3, pages 385-412.
Read now
Read now
Icilio Cavero & William Crumb. (2006) Moving towards better predictors of drug-induced Torsade de Pointes. Expert Opinion on Drug Safety 5:2, pages 335-340.
Read now
Read now
Gilles Hanton & Lorraine Tilbury. (2006) Cardiac safety strategies. Expert Opinion on Drug Safety 5:2, pages 329-333.
Read now
Read now
Icilio Cavero & William Crumb. (2006) Safety Pharmacology Society: 5th Annual Meeting. Expert Opinion on Drug Safety 5:1, pages 181-185.
Read now
Read now
Icilio Cavero & William Crumb. (2005) The use of electrocardiograms in clinical trials: a public discussion of the proposed ICH E14 regulatory guidance. Expert Opinion on Drug Safety 4:4, pages 795-799.
Read now
Read now
Articles from other publishers (51)
Seung-Hyun Yoon, Hyun-Lee Lee, Da Un Jeong, Ki Moo Lim, Seong-Jun Park & Ki-Suk Kim. (2023) Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive in vitro proarrhythmia assay (CiPA). Frontiers in Pharmacology 14.
Crossref
Crossref
Jacqueline Wen Hui Leow, Yuxiang Gu & Eric Chun Yong Chan. (2023) Investigating the relevance of CYP2J2 inhibition for drugs known to cause intermediate to high risk torsades de pointes. European Journal of Pharmaceutical Sciences 187, pages 106475.
Crossref
Crossref
Jianyong Ma, Nathan Y. Wang, Ravikumar Jagani & Hong-Sheng Wang. (2023) Proarrhythmic toxicity of low dose bisphenol A and its analogs in human iPSC-derived cardiomyocytes and human cardiac organoids through delay of cardiac repolarization. Chemosphere 328, pages 138562.
Crossref
Crossref
Jin Ryeol An, Seo-Yeong Mun, In Kyo Jung, Kwan Soo Kim, Chan Hyeok Kwon, Sun Ok Choi & Won Sun Park. (2023)
New
in vitro
multiple cardiac ion channel screening system for preclinical Torsades de Pointes risk prediction under the Comprehensive
in vitro
Proarrhythmia Assay concepta
. The Korean Journal of Physiology & Pharmacology 27:3, pages 267-275.
Crossref
Crossref
Da Un Jeong, Yedam Yoo, Aroli Marcellinus & Ki Moo Lim. (2023) Application of Convolutional Neural Networks Using Action Potential Shape for In-Silico Proarrhythmic Risk Assessment. Biomedicines 11:2, pages 406.
Crossref
Crossref
Da Un Jeong, Rakha Zharfarizqi Danadibrata, Aroli Marcellinus & Ki Moo Lim. (2022) Validation of in silico biomarkers for drug screening through ordinal logistic regression. Frontiers in Physiology 13.
Crossref
Crossref
Kozue Murata & Hidetoshi Masumoto. (2022) Systems for the Functional Evaluation of Human Heart Tissues Derived from Pluripotent Stem Cells. Stem Cells 40:6, pages 537-545.
Crossref
Crossref
Yedam Yoo, Aroli Marcellinus, Da Un Jeong, Ki-Suk Kim & Ki Moo Lim. (2021) Assessment of Drug Proarrhythmicity Using Artificial Neural Networks With in silico Deterministic Model Outputs. Frontiers in Physiology 12.
Crossref
Crossref
Soo-Dam Kim, Jae-Ho Yang, Eun-Bin Kwag, Ji-Hye Park, So-Jung Park & Hwa-Seung Yoo. (2021) Nonclinical Safety Pharmacology Study of the Herbal Product HAD-B1. Evidence-Based Complementary and Alternative Medicine 2021, pages 1-10.
Crossref
Crossref
Ellen Fritsche, Thomas Haarmann‐Stemmann, Julia Kapr, Saskia Galanjuk, Julia Hartmann, Peter R. Mertens, Angela A. M. Kämpfer, Roel P. F. Schins, Julia Tigges & Katharina Koch. (2020) Stem Cells for Next Level Toxicity Testing in the 21st Century. Small 17:15.
Crossref
Crossref
Mosha Abulaiti, Yaxiaer Yalikun, Kozue Murata, Asako Sato, Mustafa M. Sami, Yuko Sasaki, Yasue Fujiwara, Kenji Minatoya, Yuji Shiba, Yo Tanaka & Hidetoshi Masumoto. (2020) Establishment of a heart-on-a-chip microdevice based on human iPS cells for the evaluation of human heart tissue function. Scientific Reports 10:1.
Crossref
Crossref
Najah Abi-Gerges, Paul E. Miller & Andre Ghetti. (2020) Human Heart Cardiomyocytes in Drug Discovery and Research: New Opportunities in Translational Sciences. Current Pharmaceutical Biotechnology 21:9, pages 787-806.
Crossref
Crossref
Michael K. Pugsley, Matthew M. Abernathy, Tiffany Montevideo Whitney, Simon Authier, John J. Renger & Michael J. Curtis. 2019. Advanced Issue Resolution in Safety Pharmacology. Advanced Issue Resolution in Safety Pharmacology
303
338
.
Joshua Mayourian, Eric A. Sobie & Kevin D. Costa. 2018. Experimental Models of Cardiovascular Diseases. Experimental Models of Cardiovascular Diseases
17
35
.
Fei Pei, Junjie Jiang, Shuyun Bai, Henghua Cao, Luyang Tian, Ya Zhao, Chuanxiu Yang, Haiheng Dong & Yue Ma. (2017) Chemical-defined and albumin-free generation of human atrial and ventricular myocytes from human pluripotent stem cells. Stem Cell Research 19, pages 94-103.
Crossref
Crossref
Xiaoyu Zhang, Liang Guo, Haoyu Zeng, Stephen L. White, Michael Furniss, Bharathi Balasubramanian, Edward Lis, Armando Lagrutta, Frederick Sannajust, Li Leyna Zhao, Biao Xi, Xiaobo Wang, Myrtle Davis & Yama A. Abassi. (2016) Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment. Journal of Pharmacological and Toxicological Methods 81, pages 201-216.
Crossref
Crossref
Icilio Cavero, Jean-Michel Guillon, Veronique Ballet, Mike Clements, Jean-Frédéric Gerbeau & Henry Holzgrefe. (2016) Comprehensive in vitro Proarrhythmia Assay (C i PA): Pending issues for successful validation and implementation. Journal of Pharmacological and Toxicological Methods 81, pages 21-36.
Crossref
Crossref
Praveen Shukla, Priyanka Garg & Joseph C. Wu. 2016. Drug Discovery Toxicology. Drug Discovery Toxicology
346
364
.
Omi Bajracharya, P. Ravi Shankar & Nisha Jha. 2015. Heart and Toxins. Heart and Toxins
305
339
.
Michael K. Pugsley, Michael J. Curtis & Eric S. Hayes. 2015. Principles of Safety Pharmacology. Principles of Safety Pharmacology
149
203
.
Sarfaraz K. Niazi. 2014. Handbook of Bioequivalence Testing. Handbook of Bioequivalence Testing
756
787
.
Brian R. Berridge, Syril D. Pettit & R. Dustan Sarazan. (2014) Opportunities to meet clinical cardio-oncology needs with new approaches to non-clinical safety assessment. Progress in Pediatric Cardiology 36:1-2, pages 31-32.
Crossref
Crossref
Ashish Mehta, YingYing Chung, Glen Lester Sequiera, Philip Wong, Reginald Liew & Winston Shim. (2013) Pharmacoelectrophysiology of Viral-Free Induced Pluripotent Stem Cell–Derived Human Cardiomyocytes. Toxicological Sciences 131:2, pages 458-469.
Crossref
Crossref
Brian R. Berridge, Peter Hoffmann, James R. Turk, Frank Sellke, Gary Gintant, Gerald Hirkaler, Kevin Dreher, A. Eric Schultze, Dana Walker, Nick Edmunds, Wendy Halpern, James Falls, Marty Sanders & Syril D. Pettit. (2013) Integrated and translational nonclinical in vivo cardiovascular risk assessment: Gaps and opportunities. Regulatory Toxicology and Pharmacology 65:1, pages 38-46.
Crossref
Crossref
Franz J. Hock. 2013. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays
5
16
.
Supratik Kar & Kunal Roy. (2012) Prediction of hERG Potassium Channel Blocking Actions Using Combination of Classification and Regression Based Models: A Mixed Descriptors Approach. Molecular Informatics 31:11-12, pages 879-894.
Crossref
Crossref
Fabio Cerignoli, David Charlot, Ross Whittaker, Randy Ingermanson, Piyush Gehalot, Alex Savchenko, David J. Gallacher, Rob Towart, Jeffrey H. Price, Patrick M. McDonough & Mark Mercola. (2012) High throughput measurement of Ca2+ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry. Journal of Pharmacological and Toxicological Methods 66:3, pages 246-256.
Crossref
Crossref
P‐J Guns, DM Johnson, J Van Op den bosch, E Weltens & J Lissens. (2012) The electro‐mechanical window in anaesthetized guinea pigs: a new marker in screening for Torsade de Pointes risk. British Journal of Pharmacology 166:2, pages 689-701.
Crossref
Crossref
Luis G ValerioJrJr. (2011) In silicotoxicology models and databases as FDA Critical Path Initiative toolkits. Human Genomics 5:3.
Crossref
Crossref
Harold Ayetey. 2011. Translational Stem Cell Research. Translational Stem Cell Research
77
90
.
Daniel W. Beacham, Trillium Blackmer, Michael O’ Grady & George T. Hanson. (2010) Cell-Based Potassium Ion Channel Screening Using the FluxOR™ Assay. SLAS Discovery 15:4, pages 441-446.
Crossref
Crossref
Stefan R. Braam, Leon Tertoolen, Anja van de Stolpe, Thomas Meyer, Robert Passier & Christine L. Mummery. (2010) Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Research 4:2, pages 107-116.
Crossref
Crossref
Stefan R. Braam, Robert Passier & Christine L. Mummery. (2009) Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. Trends in Pharmacological Sciences 30:10, pages 536-545.
Crossref
Crossref
Liang Guo, Zedong Dong & Heather Guthrie. (2009) Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. Journal of Pharmacological and Toxicological Methods 60:2, pages 130-151.
Crossref
Crossref
Jonathan P. Piccini, David J. Whellan, Brian R. Berridge, John K. Finkle, Syril D. Pettit, Norman Stockbridge, Jean-Pierre Valentin, Hugo M. Vargas & Mitchell W. Krucoff. (2009) Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative. American Heart Journal 158:3, pages 317-326.
Crossref
Crossref
Tina C. Stummann, Mario Beilmann, Göran Duker, Berengere Dumotier, J. Magnus Fredriksson, Robin L. Jones, Marina Hasiwa, Y. James Kang, Carl-Fredrik Mandenius, Thomas Meyer, Giorgio Minotti, Y. Jean-Pierre Valentin, Bernd J. Zünkler & Susanne Bremer. (2009) Report and Recommendations of the Workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity. Cardiovascular Toxicology 9:3, pages 107-125.
Crossref
Crossref
Emanuel Raschi, Valentina Vasina, Elisabetta Poluzzi & Fabrizio De Ponti. (2008) The hERG K+ channel: target and antitarget strategies in drug development. Pharmacological Research 57:3, pages 181-195.
Crossref
Crossref
Torsten Christ, Erich Wettwer, Melinda Wuest, Manfred Braeter, Frank Donath, Pascal Champeroux, Serge Richard & Ursula Ravens. (2007) Electrophysiological profile of propiverine – relationship to cardiac risk. Naunyn-Schmiedeberg's Archives of Pharmacology 376:6, pages 431-440.
Crossref
Crossref
Fabrizio De Ponti. 2008. Antitargets. Antitargets
53
88
.
Christophe Arbus, Amine Benyamina, Pierre-Michel Llorca, Franck Baylé, Norbert Bromet, Frédéric Massiere, Ricardo P. Garay & Ahcène Hameg. (2007) Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. European Journal of Pharmaceutical Sciences 32:4-5, pages 357-366.
Crossref
Crossref
Henry H. Holzgrefe, Icilio Cavero, Lewis V. Buchanan, Michael W. Gill & Stephen K. Durham. (2007) Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: Effects of moxifloxacin. Journal of Pharmacological and Toxicological Methods 55:3, pages 244-254.
Crossref
Crossref
Gilles Hanton. (2007) Preclinical Cardiac Safety Assessment??of Drugs. Drugs in R & D 8:4, pages 213-228.
Crossref
Crossref
Akira Takahara, Hideki Nakamura, Hideaki Nouchi, Takeshi Tamura, Toshikazu Tanaka, Hideaki Shimada, Miku Tamura, Noriko Tsuruoka, Kentaro Takeda, Hikaru Tanaka, Koki Shigenobu, Keitaro Hashimoto & Atsushi Sugiyama. (2007) Analysis of Arrhythmogenic Profile in a Canine Model of Chronic Atrioventricular Block by Comparing In Vitro Effects of the Class III Antiarrhythmic Drug Nifekalant on the Ventricular Action Potential Indices Between Normal Heart and Atrioventricular Block Heart. Journal of Pharmacological Sciences 103:2, pages 181-188.
Crossref
Crossref
Michael W. Schmitt, Friedrich Von Landenberg, Hartmut Poth, Elmar Wimmer, Thomas Goddemeier & Icilio Cavero. (2007) Simple-to-use, reference criteria for revealing drug-induced QT interval prolongation in conscious dogs. European Journal of Pharmacology 554:1, pages 46-52.
Crossref
Crossref
Bernd J. Zünkler. (2006) Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects. Pharmacology & Therapeutics 112:1, pages 12-37.
Crossref
Crossref
Michael K. Pugsley & Michael J. Curtis. (2006) Safety pharmacology in focus: New methods developed in the light of the ICH S7B guidance document. Journal of Pharmacological and Toxicological Methods 54:2, pages 94-98.
Crossref
Crossref
William Redfern & Ian Wakefield. 2006. Toxicological Testing Handbook. Toxicological Testing Handbook
33
78
.
William Crumb, Pierre-Michel Llorca, Christophe Lancon, George P. Thomas, Ricardo P. Garay & Ahcène Hameg. (2006) Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs. European Journal of Pharmacology 532:3, pages 270-278.
Crossref
Crossref
Franz J. Hock. 2006. Drug Discovery and Evaluation. Drug Discovery and Evaluation
5
13
.
Michael K. Pugsley. (2005) Methodology used in safety pharmacology: Appraisal of the state-of-the-art, the regulatory issues and new directions. Journal of Pharmacological and Toxicological Methods 52:1, pages 1-5.
Crossref
Crossref
Jianyong Ma & Hong-Sheng Wang. (2022) Proarrhythmic Toxicity of Low Dose Bisphenol a in Human Ipsc-Derived Cardiac Myocytes Through Delay of Cardiac Repolarization and Inhibition of the Herg Channel. SSRN Electronic Journal.
Crossref
Crossref